Feature

Comorbidities the rule in New York’s COVID-19 deaths


 

In New York state, just over 86% of reported COVID-19 deaths involved at least one comorbidity, according to the state’s department of health.

As of midnight on April 6, there had been 5,489 fatalities caused by COVID-19 in the state, of which 86.2% (4,732) had at least one underlying condition, the New York State Department of Health reported April 7 on its COVID-19 tracker.

The leading comorbidity, seen in 55.4% of all deaths, was hypertension. In comparison, a recent estimate from the U.S. Department of Health & Human Services put the prevalence of high blood pressure at about 45% in the overall adult population.

In New York, the rest of the 10 most common comorbidities in COVID-19 fatalities were diabetes (37.3%), hyperlipidemia (18.5%), coronary artery disease (12.4%), renal disease (11.0%), dementia (9.1%), chronic obstructive pulmonary disease (8.3%), cancer (8.1%), atrial fibrillation (7.1%), and heart failure (7.1%), the NYSDOH said.

Other data on the tracker site show that 63% of all deaths involved a patient who was aged 70 years or older and that 61% of COVID-19 patients who have died in New York were male and 38.8% were female (sex unknown for 0.2%). Among all individuals who have tested positive, 54.8% were male and 44.6% were female (sex unknown for 0.6%).

As of the end of day on April 6, a total of 340,058 persons had been tested in the state and 40.8% (138,863) were positive for the SARS-CoV-2 virus. By county, the highest positive rates are in New York City: Queens at 57.4%, Brooklyn at 52.4%, and the Bronx at 52.3%, according to the NYSDOH.

Recommended Reading

Nearly 24 tests for the novel coronavirus are available
Covid ICYMI
NCCN panel: Defer nonurgent skin cancer care during pandemic
Covid ICYMI
AMA president calls for greater reliance on science in COVID-19 fight
Covid ICYMI
Tips for self-care during the COVID-19 crisis
Covid ICYMI
COVID-19 linked to multiple cardiovascular presentations
Covid ICYMI
‘The kids will be all right,’ won’t they?
Covid ICYMI
Conducting cancer trials amid the COVID-19 pandemic
Covid ICYMI
Treatment for RA, SpA may not affect COVID-19 severity
Covid ICYMI
Treating lung cancer in COVID-19 times: Update from experts
Covid ICYMI
SARS-CoV-2 escapes cotton, surgical masks of infected
Covid ICYMI